How pre-marketing data can be used for predicting the weight of drug interactions in clinical practice

Research output: Contribution to journalArticle

Abstract

Abstract Unexpected drug interactions have led to the withdrawal of many drugs, raising concern about the gap between what is known at the time of approval and the risk of serious effects in the longer term, particularly in high-risk populations generally excluded from drug development. This is because the majority of drug interaction studies are done using in vitro methods, or in healthy young volunteers who may not reflect the complexity of patients, and the settings in which the drug will be used in clinical practice. Pre-marketing interaction studies should therefore be designed to make information easily accessible and clinically transferable. They should be adequate in terms of sample size, population, comorbidity, phenotyping and/or genotyping, end-points and outcome measures, and conducted in conditions of dose, route and timing of co-administration that reproduce the proposed therapeutic indications of the new drug. Although young volunteers have the advantage of minimizing some confounding effects introduced by diseases or polypharmacy, patients drawn from populations for whom the drug is intended would be more relevant and accurate, providing the studies are feasible and safe.

Original languageEnglish
Pages (from-to)217-221
Number of pages5
JournalEuropean Journal of Internal Medicine
Volume24
Issue number3
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Marketing
Drug Interactions
Weights and Measures
Pharmaceutical Preparations
Population
Polypharmacy
Sample Size
Comorbidity
Volunteers
Healthy Volunteers
Outcome Assessment (Health Care)
Therapeutics

Keywords

  • Clinical practice need
  • Drug-interactions
  • Pre-marketing information

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{4de2d8445b2b4e92a4725e1f24601398,
title = "How pre-marketing data can be used for predicting the weight of drug interactions in clinical practice",
abstract = "Abstract Unexpected drug interactions have led to the withdrawal of many drugs, raising concern about the gap between what is known at the time of approval and the risk of serious effects in the longer term, particularly in high-risk populations generally excluded from drug development. This is because the majority of drug interaction studies are done using in vitro methods, or in healthy young volunteers who may not reflect the complexity of patients, and the settings in which the drug will be used in clinical practice. Pre-marketing interaction studies should therefore be designed to make information easily accessible and clinically transferable. They should be adequate in terms of sample size, population, comorbidity, phenotyping and/or genotyping, end-points and outcome measures, and conducted in conditions of dose, route and timing of co-administration that reproduce the proposed therapeutic indications of the new drug. Although young volunteers have the advantage of minimizing some confounding effects introduced by diseases or polypharmacy, patients drawn from populations for whom the drug is intended would be more relevant and accurate, providing the studies are feasible and safe.",
keywords = "Clinical practice need, Drug-interactions, Pre-marketing information",
author = "Silvio Caccia and Luca Pasina and Alessandro Nobili",
year = "2013",
month = "4",
doi = "10.1016/j.ejim.2012.12.006",
language = "English",
volume = "24",
pages = "217--221",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - How pre-marketing data can be used for predicting the weight of drug interactions in clinical practice

AU - Caccia, Silvio

AU - Pasina, Luca

AU - Nobili, Alessandro

PY - 2013/4

Y1 - 2013/4

N2 - Abstract Unexpected drug interactions have led to the withdrawal of many drugs, raising concern about the gap between what is known at the time of approval and the risk of serious effects in the longer term, particularly in high-risk populations generally excluded from drug development. This is because the majority of drug interaction studies are done using in vitro methods, or in healthy young volunteers who may not reflect the complexity of patients, and the settings in which the drug will be used in clinical practice. Pre-marketing interaction studies should therefore be designed to make information easily accessible and clinically transferable. They should be adequate in terms of sample size, population, comorbidity, phenotyping and/or genotyping, end-points and outcome measures, and conducted in conditions of dose, route and timing of co-administration that reproduce the proposed therapeutic indications of the new drug. Although young volunteers have the advantage of minimizing some confounding effects introduced by diseases or polypharmacy, patients drawn from populations for whom the drug is intended would be more relevant and accurate, providing the studies are feasible and safe.

AB - Abstract Unexpected drug interactions have led to the withdrawal of many drugs, raising concern about the gap between what is known at the time of approval and the risk of serious effects in the longer term, particularly in high-risk populations generally excluded from drug development. This is because the majority of drug interaction studies are done using in vitro methods, or in healthy young volunteers who may not reflect the complexity of patients, and the settings in which the drug will be used in clinical practice. Pre-marketing interaction studies should therefore be designed to make information easily accessible and clinically transferable. They should be adequate in terms of sample size, population, comorbidity, phenotyping and/or genotyping, end-points and outcome measures, and conducted in conditions of dose, route and timing of co-administration that reproduce the proposed therapeutic indications of the new drug. Although young volunteers have the advantage of minimizing some confounding effects introduced by diseases or polypharmacy, patients drawn from populations for whom the drug is intended would be more relevant and accurate, providing the studies are feasible and safe.

KW - Clinical practice need

KW - Drug-interactions

KW - Pre-marketing information

UR - http://www.scopus.com/inward/record.url?scp=84875217006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875217006&partnerID=8YFLogxK

U2 - 10.1016/j.ejim.2012.12.006

DO - 10.1016/j.ejim.2012.12.006

M3 - Article

C2 - 23279878

AN - SCOPUS:84875217006

VL - 24

SP - 217

EP - 221

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

IS - 3

ER -